CMV Retinitis: Protecting Your Vision When Your Immune System Is Weakened
Understanding CMV Retinitis
CMV retinitis is caused by cytomegalovirus, a virus from the herpesvirus family that lives quietly in most people without causing harm. When the immune system is severely weakened, the virus can reactivate and begin damaging the retina, the light-sensitive tissue at the back of the eye that makes vision possible.
The virus infects all layers of the retina, including the retinal pigment epithelium (RPE), a thin supportive layer underneath the retina. Infected cells become abnormal and begin to die. Without treatment, the area of damage spreads outward, destroying healthy retinal tissue as it goes.
Retina specialists often describe the appearance of CMV retinitis as resembling a pizza pie. This refers to the combination of white, dying retinal tissue mixed with areas of reddish bleeding. As the infection progresses, more and more retinal cells are destroyed, and vision in the affected area is lost.
Even after successful treatment, cytomegalovirus stays dormant in certain immune cells in the body. If the immune system weakens again, whether from disease, medications, or other causes, the virus can reactivate and cause a new episode of retinitis. This is why long-term monitoring remains essential.
Who Is at Risk for CMV Retinitis
CMV retinitis almost always occurs in people whose T-cells, the part of the immune system responsible for keeping the virus inactive, are not functioning properly. Several medical conditions and treatments can create this vulnerability.
The most well-known risk group is people living with HIV, particularly those with advanced AIDS. The infection typically develops when CD4+ T-cell counts fall below 50 cells per microliter. It rarely occurs when counts stay above 100 cells per microliter. People not receiving antiretroviral treatment, or those whose treatment has stopped working, are at the highest risk.
People who have received a solid organ transplant take immunosuppressive medications to prevent their body from rejecting the new organ. These medications reduce immune defenses and can allow CMV to reactivate. The risk is especially high for patients who had never been exposed to CMV before receiving an organ from a donor who carries the virus.
Other groups can also develop CMV retinitis when their immune system is severely suppressed. These include people undergoing chemotherapy, those taking strong medications for autoimmune conditions, and newborns with congenital immune deficiencies.
- Patients receiving cancer chemotherapy
- People on long-term immunosuppressive therapy for autoimmune diseases
- Newborns with congenital immune system problems
- Elderly individuals with significantly reduced immune function
In some cases, strong immunosuppression applied locally inside the eye can also create enough vulnerability for CMV retinitis to develop, even when the rest of the body's immune system is relatively intact.
Signs and Symptoms to Watch For
CMV retinitis does not always cause noticeable symptoms right away, which makes it particularly dangerous for people at risk. Knowing what to watch for and when to act quickly can make a meaningful difference in protecting your vision.
In many cases, CMV retinitis causes no symptoms at all in its earliest stages. When symptoms do appear, the most common is new floaters, which are small spots, dots, or cobweb-like shapes that drift across your field of vision. Any new floaters in someone with a weakened immune system deserve prompt evaluation.
As CMV retinitis advances, a shadow or dark area may appear in your side (peripheral) vision. This shadow can slowly expand as more retina is damaged. Blurred vision and visual distortions may also develop over time.
If the infection spreads to the macula, which is the central area of the retina responsible for sharp, detailed vision, significant central vision loss can occur. This type of vision loss can be long-lasting and may not fully recover even after treatment.
Certain vision changes are a medical emergency. If you have a weakened immune system and experience any of the following, seek immediate care from a retina specialist or go to an emergency room right away.
- A sudden large increase in floaters
- Flashes of light in your vision
- A dark curtain or shadow spreading across part of your vision
- Sudden loss of vision in one eye
These symptoms may signal rapidly progressing CMV retinitis or a retinal detachment, both of which require urgent treatment to prevent permanent vision loss.
How CMV Retinitis Is Diagnosed
Accurate diagnosis is the first step toward protecting your vision. Our retina specialists use a combination of examination and advanced imaging to identify CMV retinitis and determine how far it has spread.
The primary way CMV retinitis is diagnosed is through a dilated eye examination. Dilation involves using eye drops to widen the pupil so the retina can be seen clearly. A retina specialist uses specialized lenses and instruments to examine the back of the eye in detail. The characteristic appearance of white, dead tissue mixed with hemorrhage is often enough to confirm the diagnosis.
Because early CMV retinitis often causes no symptoms, regular screening is critical for people at high risk. Patients with CD4 counts below 50 cells per microliter should have eye examinations at least every three months. Catching the infection early, before significant damage occurs, gives treatment the best chance of preserving vision.
In some cases, additional tests help confirm the diagnosis or track the extent of damage. Optical coherence tomography (OCT) creates detailed cross-sectional images of the retinal layers. Fundus photography takes high-resolution pictures of the retina to monitor changes over time. When the diagnosis is uncertain, a small fluid sample from inside the eye can be tested for CMV genetic material using a method called polymerase chain reaction (PCR).
Treatment Options for CMV Retinitis
Treatment is focused on stopping the virus from spreading further, preserving as much vision as possible, and supporting immune recovery. Our retina specialists individualize every treatment plan based on the location of the infection, its severity, and the patient's overall medical condition.
The main treatment for CMV retinitis is antiviral medication that works throughout the body. Several approved options are available, including ganciclovir, valganciclovir, foscarnet, and cidofovir. Oral valganciclovir is the most commonly used option today because it is convenient and absorbs well. Treating the whole body matters because CMV can affect organs beyond the eyes.
Treatment usually begins with a higher induction dose for two to three weeks while the retinitis is brought under control. After that, the dose is reduced to a lower maintenance level to keep the virus suppressed.
In some situations, a retina specialist may also deliver antiviral medication directly into the eye through an intravitreal injection (an injection into the gel-filled interior of the eye). Ganciclovir and foscarnet can both be given this way. These injections are often used alongside systemic therapy early in treatment to achieve faster control, especially when the infection is close to the macula or optic nerve.
For patients with HIV, restoring immune function through highly active antiretroviral therapy (HAART) is the most important long-term strategy. The widespread use of HAART has dramatically reduced the rate of CMV retinitis and significantly lowered the risk of disease progression. When CD4+ T-cell counts rise and remain at a healthy level, the risk of CMV reactivation drops considerably. Under close medical supervision, maintenance antiviral therapy may eventually be stopped once immune recovery is sustained.
Research into adoptive cell transfer, a process that involves infusing patients with immune cells specifically trained to fight CMV, has shown early promise. This approach may be particularly useful for transplant recipients who need to stay on immunosuppressive medications. While this therapy is still being studied, it represents a meaningful direction in the management of difficult or recurring cases.
What to Expect During and After Treatment
Understanding the treatment process helps patients stay engaged in their care and recognize important changes along the way. Close communication between our retina team and a patient's primary medical providers is a central part of successful management.
During the first two to three weeks of treatment, the infection is closely monitored to confirm that it is stabilizing. Eye examinations are performed frequently to check whether the borders of the infected area have stopped expanding. If intravitreal injections are part of the plan, patients may receive several injections during this initial period.
Most antiviral medications used for CMV retinitis can have side effects. Ganciclovir and valganciclovir may lower blood cell counts, requiring regular blood monitoring. Foscarnet can affect kidney function and electrolyte balance. Our team works closely with a patient's broader medical providers to watch for these effects throughout treatment.
The long-term outlook depends heavily on immune recovery. Retinal tissue destroyed by the virus does not regenerate, so vision lost before treatment begins is typically not recoverable. This is why early detection matters so much. With modern treatment and immune recovery, the risk of serious complications such as retinal detachment has improved significantly compared to earlier eras.
After the infection is stabilized, patients continue on a lower maintenance dose of antiviral medication for an extended period. Regular follow-up with a retina specialist is essential to watch for any signs of reactivation. If immune function recovers sufficiently and remains stable, maintenance therapy may be carefully tapered with close supervision. Even after treatment ends, ongoing eye examinations remain important.
Living Well With CMV Retinitis
Managing CMV retinitis is a long-term commitment that goes beyond treating the eye infection itself. Supporting overall health and adjusting to any lasting vision changes are both important parts of life after diagnosis.
Keeping the immune system as strong as possible is the most powerful tool against recurrence. For people with HIV, this means consistent adherence to antiretroviral therapy every day. For transplant recipients, it means working closely with a transplant team to find the right balance between preventing rejection and minimizing infection risk. Regular blood tests and medical checkups to track immune function are a critical part of ongoing care.
Some patients experience lasting vision changes after CMV retinitis, particularly when the macula or optic nerve has been affected. Low vision rehabilitation services can help patients make the most of their remaining vision. These services may include magnification aids, strategies for everyday tasks, and adjustments to lighting and contrast that make a real difference in daily life.
Facing a vision-threatening condition alongside an underlying immune disorder can be emotionally difficult. Support groups, counseling, and patient advocacy organizations for people with visual impairment or HIV can offer meaningful help. Our retina specialists are glad to connect patients with appropriate community resources and support services.
When to See a Retina Specialist
Timely care is essential with CMV retinitis. Whether you are at risk and have no symptoms yet, or you have noticed something concerning, there are clear situations that call for prompt evaluation.
Anyone with severely weakened immune function should have routine eye examinations by a retina specialist, even with no vision complaints. This is especially important for patients with CD4 counts below 50 cells per microliter, those who have recently started or changed immunosuppressive therapy, and transplant recipients within the first year after surgery. Early detection before symptoms develop gives treatment the best chance of success.
Do not wait to be seen if you have a weakened immune system and experience sudden changes in your vision. A sudden increase in floaters, new flashes of light, a shadow or curtain moving across your visual field, or sudden loss of vision in one eye all require same-day or emergency evaluation. Prompt treatment can prevent irreversible damage to vision that may otherwise be lost permanently.
Frequently Asked Questions
These answers address questions we hear from patients and families navigating a CMV retinitis diagnosis.
Yes, reactivation is possible any time the immune system weakens again. Even if treatment successfully halts the infection, the virus remains dormant in the body. If you stop maintenance antiviral therapy before your immune system has fully recovered, or if your immune function declines for any reason, the retinitis can return. This is why follow-up appointments with your retina specialist should never be skipped, even when you feel well.
The retinitis itself is not contagious, but the underlying cytomegalovirus can be spread through bodily fluids such as saliva, blood, and breast milk. Most people who are exposed to CMV develop no symptoms at all because a healthy immune system keeps it dormant. The retinitis complication only develops in people whose immune systems are severely compromised, so casual contact with someone who has CMV retinitis does not place healthy individuals at meaningful risk.
Treatment stops the infection from spreading further, but it cannot restore retinal tissue that has already been destroyed. Vision that was lost before treatment began is generally not recoverable. Patients who are diagnosed early, before significant retinal damage has occurred, have the best chance of preserving useful vision. If the macula was affected, some degree of lasting central vision impairment is possible even after the infection is controlled.
The initial induction phase typically lasts two to three weeks. After that, a lower-dose maintenance regimen continues for months or longer, depending on immune recovery. For people with HIV who achieve strong, sustained immune recovery through antiretroviral therapy, it may eventually be appropriate to stop maintenance treatment under careful medical supervision. Patients who must remain on long-term immunosuppression, such as transplant recipients, may need extended or indefinite monitoring and treatment adjustments.
For people with HIV, the most effective prevention is keeping CD4+ T-cell counts well above 50 cells per microliter through consistent antiretroviral therapy. For transplant recipients, preventive antiviral medications may be prescribed during the period of highest risk. Regular dilated eye examinations are a critical preventive measure for all high-risk individuals, since early detection before vision loss occurs gives treatment the greatest chance of success. Speak with your specialist about the right screening schedule for your situation.
Expert Retina Care at Rhode Island Eye Institute
CMV retinitis is a complex, vision-threatening condition that requires the expertise of a dedicated retina specialist and a coordinated care team. At Rhode Island Eye Institute, our fellowship-trained retina specialists bring advanced diagnostic technology and individualized treatment planning to every patient. We are proud to serve patients across Rhode Island and southeastern Massachusetts, and we are here to help you protect and preserve your vision at every stage of care.